BioCryst Pharmaceuticals (NASDAQ: BCRX) revenue
BioCryst Pharmaceuticals reported revenue of $874.8m for fiscal 2025, 94.1% more than in fiscal 2024 ($450.7m). Since fiscal 2016 its revenue has grown by 3,219.7%, an average growth of 47.6% a year.
BioCryst Pharmaceuticals has grown its revenue for 5 years in a row, and fiscal 2025 is the highest of its 10 fiscal years on record. The biggest drop was in fiscal 2020, −63.5%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $874.8m | +94.1% | $341.0m | 39.0% |
| 2024 | $450.7m | +36.0% | −$2.5m | −0.6% |
| 2023 | $331.4m | +22.4% | −$103.7m | −31.3% |
| 2022 | $270.8m | +72.3% | −$148.4m | −54.8% |
| 2021 | $157.2m | +782.4% | −$177.7m | −113.1% |
| 2020 | $17.8m | −63.5% | −$174.8m | −981.1% |
| 2019 | $48.8m | +136.5% | −$99.5m | −203.7% |
| 2018 | $20.7m | −18.0% | −$94.2m | −456.2% |
| 2017 | $25.2m | −4.4% | −$57.4m | −227.9% |
| 2016 | $26.4m | — | −$48.6m | −184.4% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
BioCryst Pharmaceuticals revenue compared with its sector
By revenue for its latest fiscal year, BioCryst Pharmaceuticals ranks 159th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; BioCryst Pharmaceuticals, 94.1%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 157th | ANI Pharmaceuticals | $883.4m | 43.8% |
| 158th | Nutex Health | $875.3m | 82.4% |
| 159th | BioCryst Pharmaceuticals | $874.8m | 94.1% |
| 160th | Warby Parker | $871.9m | 13.0% |
| 161st | Neogen | $870.4m | −2.7% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of BioCryst Pharmaceuticals
- How much revenue did BioCryst Pharmaceuticals make in fiscal 2025?
- BioCryst Pharmaceuticals reported revenue of $874.8m for fiscal 2025, compared with $450.7m in fiscal 2024.
- How much has the revenue of BioCryst Pharmaceuticals grown?
- Between fiscal 2016 and fiscal 2025 it went from $26.4m to $874.8m: 3,219.7% more, an average growth of 47.6% a year.
- What was the best year for revenue at BioCryst Pharmaceuticals?
- Of its last 10 fiscal years, fiscal 2025, with $874.8m.
- Where does BioCryst Pharmaceuticals rank in its sector by revenue?
- It ranks 159th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for BioCryst Pharmaceuticals come from?
- From the annual report (Form 10-K) that BioCryst Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that BioCryst Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on BioCryst Pharmaceuticals: the BioCryst Pharmaceuticals page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.